It has been reported that calcium channel blockers induce a rise in serum ciclosporin as estimated with the radioimmunoassay (RIA) kits based on polyclonal antibody [1][2][3]. Increased ciclosporin blood concentrations may be due to interference by nicardipine with ciclosporin clearance, probably because both drugs are predominantly eliminated by the liver via cytochrome P 450 hepatic enzymes. Recently, a new specific monoclonal RIA for the therapeutic monitoring of ciclosporin has replaced the old RIA kits. We report the effect of nicardipine on ciclosporin levels using both RIA kits. A 60-year-old woman was given ciclosporin for idiopathic uveitis. Nicardipine 20 mg three times daily was associated in a prospective attempt to prevent ciclospo-rin-induced renal damage. Six months later her serum creatinine was 90 jxmol/l, and the daily ciclosporin dosage was 4 mg/kg with a serum through level of 152 ng/ml and 98 ng/ml with the polyclonal and monoclonal RIA kits, respectively. Nicardipine was then interrupted, while ciclosporin was kept unchanged. Nicardipine withdrawal induced a sharp decline in serum ciclosporin levels estimated with both RIA kits ( fig. 1 ). Renal function remained unchanged. Our results strongly suggest that nicardipine affects either ciclosporin bioavailability or hepatic metabolism and not the metabolism of ciclosporin metabolites. When monitoring ciclosporin therapy with a specific monoclonal RIA one should be aware that nicardipine increases serum ciclosporin levels.
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